GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Celgene Corporation (CELG) [hlAlert]

Rating:
Buy CELG
up 207.52 %

Celgene Corporation (CELG) rated Buy with price target $156 by Cantor Fitzgerald

Posted on: Friday,  Jul 26, 2013  8:25 AM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Celgene Corporation (NASDAQ: CELG) on 07/26/2013. Previously Cantor Fitzgerald rated Buy Celgene Corporation (NASDAQ: CELG) on 04/04/2012.,
when the stock price was $40.01. Since then, Celgene Corporation has gained 207.52% as of 01/14/2016's recent price of $123.04.
If you would have followed the previous Cantor Fitzgerald's recommendation on CELG, you would have gained 207.52% of your investment in 1380 days.

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/26/2013 8:25 AM Buy
None
71.97 78.00
as of 12/13/2013
1 Week down  -0.91 %
1 Month up  10.46 %
3 Months up  10.31 %
1 YTD up  110.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/22/2013 8:25 AM Buy
None
62.00 71.00
3/4/2013 8:25 AM Buy
None
51.68 60.50
1/14/2013 8:25 AM Buy
None
48.28 57.50
11/12/2012 8:25 AM Buy
None
38.96 48.00
9/7/2012 8:25 AM Buy
None
37.43 41.00
6/22/2012 8:25 AM Buy
None
29.93 36.50
4/4/2012 8:25 AM Buy
None
40.01 45.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy